In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Chronic Coronary Syndromes

CRT Workshop - 19 & 20 February 2020, Sheraton Amsterdam Airport, The Netherlands

19/02/2020 14:00 20/02/2020 13:00 Europe/Paris Chronic Coronary Syndromes

Access event page

contact@escardio.org DD/MM/YYYY
In-person
event

Summary

Chairpersons: Prof. Eva Prescott (ESC), Prof. William Wijns (ESC), Dr Isabelle Richard-Lordereau (Amgen), Dr Martin van Eickels (Bayer)



Objective of the workshop

To Discuss Aspects of the New ESC Stable Coronary Syndromes Guidelines.

View the Biographies

Introduction

Prof. Eva Prescott (ESC), Dr Martin Van Eickels (Bayer) & Dr Isabelle Lordereau-Richard (Amgen)

13:00 - 13:15

Why a Change of Terminology to Chronic Coronary Syndromes?

Prof. William Wijns, IE

13:15 - 14:00

Keynote Lecture - The Future Role of Imaging in Preventing Cardiovascular Disease: “Prevention 1.5“

Prof. Valentin Fuster, USA (Zoom)

SESSION 1

THE DIAGNOSTIC WORKUP OF PATIENTS WITH SUSPECTED CAD: A CHANGING LANDSCAPE
Session Chairs: Prof. Juhani Knuuti, Maria Husseini (Philips), Philippe Karam (GE Healthcare)

14:00 - 14:30

Pre-test Likelihood and Implications for Diagnostic Testing: New ESC Guidelines Recommendations

Prof. Stephan Achenbach, DE  

14:30 - 15:00

Will Coronary CTA Replace Invasive Coronary Angiography?

Prof. Jeroen Bax, NL

15:00 - 15:30

Anatomical and Functional Evaluation: Many Options, Many Strategies

Dr Victoria Delgado, NL

15:30 - 16:00

The UK as Europe’s Crystal Ball: What Has Been the Impact of NICE Recommendations on Clinical Practice

Prof. David Newby, UK

16:00 - 16:30

Diagnostic Workup for Suspected CAD: Industry Perspective

Dr Friedrich Fuchs -  Siemens, DE

SESSION 2

PATIENTS WITH ANGINA AND SUSPECTED VASOSPASTIC OR MICROVASCULAR DISEASE
Session Chairs:  Prof. Colin Berry and Prof. Eva Prescott

16:45 - 17:15

What Are the New ESC Guideline Recommendations?

Prof. Javier Escaned, ES

17:15 - 17:45

The Clinical Needs: Vasospastic and Microvascular Coronary Artery Disease

Dr Yolande Appelman, NL

17:45 - 18:15

The Medical Needs: Medical and Device Treatment Now and in the Future

Prof. Filippo Crea, IT

18:15 - 18:45

Industry View - Medical Therapy for Vasospastic and Microvascular CAD

Dr. Li-Ming Gan -AstraZeneca, SE

18:45 - 19:15

Industry View – Market Access

Dr Nick West – Abbott, USA

SESSION 3

CHRONIC CORONARY SYNDROMES: CLINICAL IMPACT OF INTENSIFIED ANTI-THROMBOTIC THERAPIES

Session Chairs:  Prof. Steffen Massberg and Prof. William Wijns
09:15 - 09:45

What Are the New ESC Guideline Recommendations for Anti-thrombotic Therapies?

Prof. Emanuele Barbato, IT

09:45 - 10:15

How to Balance Ischemic and Bleeding Risks: Clinical Impact of Intensified Anti-thrombotic Therapies

Prof. Martine Gilard, FR

10:15 - 10:45

Anti-thrombotic Therapy: Gaps in Knowledge and Upcoming Trials

Prof. Sigrun Halvorsen, NO

11:00 - 11:30

Anti-platelet Therapy: Reappraisal of Aspirin

Prof. John W McEvoy, IE

11:30 - 12:00

Industry View: What Are the New Drugs in the Pipeline?

Dr Martin van Eickels - Bayer, DE